Garenoxacin in the treatment of community-acquired pneumonia


  • Biswanath Biswas Consultant Physician, Biswas Clinic, Kolkata, West Bengal, India
  • Anoop L. Hajare Medical Services, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India
  • K. Krishnaprasad Medical Services, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India
  • Amit Bhargava Medical Services, Glenmark Pharmaceuticals Ltd., Mumbai, Maharashtra, India


Community-acquired pneumonia, Broad spectrum antibiotic, Garenoxacin, Resistance


Community-acquired pneumonia (CAP) is a major cause of adult mortality in Asia. Empirical use of antibiotics depends on the pathogens that are commonly responsible. Evolution of resistant pathogens in CAP has added to the burden of treating physicians. Microbiological culture and antibiotic sensitivity testing are helpful for the treatment of such respiratory tract infections. Klebsiella pneumoniae though uncommon pathogen of CAP has been reported in many cases. Garenoxacin a newer fluoroquinolone has found its utility in the treatment of respiratory tract infections. Providing symptomatic relief to the patient with the use of analgesics, antipyretics and cough preparations are also an essential part of the management.


Neocleous C, Gerogianni I, Gourgoulianis K, Petinaki E. Prevalence of atypical bacterial pathogens in hospitalised adult patients with community-acquired pneumonia in Central Greece. Indian J Med Microbiol. 2014;32(2):204-5.

Sun T, Sun L, Wang R, Ren X, Sui DJ, Pu C, et al. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Chin Med J (Engl). 2014;127(7):1201-5.

Kikuchi R, Watabe N, Konno T, Mishina N, Sekizawa K, Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med. 1994;150(1):251-3.

Cunha BA. Pneumonia in the elderly. Clin Microbiol Infect. 2001;7(11):581-8.

Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother. 2000;44(12):3351-6.




How to Cite

Biswas, B., Hajare, A. L., Krishnaprasad, K., & Bhargava, A. (2017). Garenoxacin in the treatment of community-acquired pneumonia. International Journal of Basic & Clinical Pharmacology, 3(6), 1093–1095. Retrieved from